HER2/neu Overexpression and Recurrence Risk in Early Stage Uterine Serous Carcinoma

被引：0
|
作者：
Blakaj, A. [1 ]
Jairam, V. [2 ]
Buza, N. [3 ]
Schwartz, P. [4 ]
Santin, A. [4 ]
Damast, S. [1 ]
机构：
[1] Yale Sch Med, Dept Therapeut Radiol, New Haven, CT USA
[2] Yale Sch Med, New Haven, CT USA
[3] Yale Sch Med, Dept Pathol, New Haven, CT USA
[4] Yale Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2018年 / 102卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2018.07.139
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1126
引用
收藏
页码：S218 / S219
页数：2
相关论文
共 50 条
  • [21] HER2 Immunohistochemistry Significantly Overestimates HER2 Amplification in Uterine Papillary Serous Carcinoma
    Mentrikoski, M. J.
    Stowman, A.
    Stoler, M. H.
    MODERN PATHOLOGY, 2014, 27 : 296A - 296A
  • [22] HER2 Immunohistochemistry Significantly Overestimates HER2 Amplification in Uterine Papillary Serous Carcinoma
    Mentrikoski, M. J.
    Stowman, A.
    Stoler, M. H.
    LABORATORY INVESTIGATION, 2014, 94 : 296A - 296A
  • [23] HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma
    Mcnamara, Blair
    Mutlu, Levent
    Greenman, Michelle
    Harold, Justin
    Santin, Alessandro
    CANCERS, 2023, 15 (16)
  • [24] Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort
    Najjar, Omar
    Erickson, Britt K.
    Klein, Molly
    Dolan, Michelle
    Shahi, Maryam
    Grandelis, Anthony
    Buza, Natalia
    Tymon-Rosario, Joan Rose
    Santin, Alessandro D.
    Ferriss, James Stuart
    Fader, Amanda Nickles
    GYNECOLOGIC ONCOLOGY, 2020, 159 (02) : E13 - E13
  • [25] Incidence and prediction of tumour recurrence of Her2/neu overexpression in bladder cancer
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (03) : 86 - 86
  • [26] OVEREXPRESSION OF HER2/NEU ONCOGENE IN HUMAN PANCREATIC-CARCINOMA
    YAMANAKA, Y
    FRIESS, H
    KOBRIN, MS
    BUCHLER, M
    KUNZ, J
    BEGER, HG
    KORC, M
    HUMAN PATHOLOGY, 1993, 24 (10) : 1127 - 1134
  • [27] Breast Carcinoma, Receptor Status, and Her2 neu Overexpression Revisited
    Puvitha, R. D.
    Shifa, S.
    INTERNATIONAL JOURNAL OF SCIENTIFIC STUDY, 2016, 3 (10) : 52 - 58
  • [28] Adding trastuzumab to carboplatin and paclitaxel improves overall survival in advanced-stage HER2/NEU overexpressing uterine serous carcinoma or carcinosarcoma
    Lu, Ting-Fang
    Lou, Sun
    Shih, Yu-Hsiang
    Chen, Yen-Fu
    Fan, Chun Ting
    Wang, Shao-Jing
    Hsu, Shih-Tien
    Liu, Chin-Ku
    Hwang, Sheau-Feng
    Lu, Chien-Hsing
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A45 - A46
  • [29] Marked Heterogeneity of HER2/NEU Gene Amplification in Endometrial Serous Carcinoma
    Buza, Natalia
    Hui, Pei
    GENES CHROMOSOMES & CANCER, 2013, 52 (12): : 1178 - 1186
  • [30] HER2 in uterine serous carcinoma: Current state and clinical perspectives
    Sanchez, Janira M. Navarro
    Finkelman, Brian S.
    Turner, Bradley M.
    Katerji, Hani
    Wang, Xi
    Varghese, Sharlin
    Wang, Tiannan
    Peng, Yan
    Hicks, David G.
    Zhang, Huina
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2023, 160 (04) : 341 - 351
12345